ACER THERAPEUTICS INC (ACER) Stock Price & Overview
NASDAQ:ACER • US00444P1084
Current stock price
The current stock price of ACER is 0.9 USD. Today ACER is up by 3.41%. In the past month the price increased by 20%. In the past year, price decreased by -26.83%.
ACER Key Statistics
- Market Cap
- 22.014M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.66
- Dividend Yield
- N/A
ACER Stock Performance
ACER Stock Chart
ACER Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ACER. When comparing the yearly performance of all stocks, ACER turns out to be only a medium performer in the overall market: it outperformed 51.09% of all stocks.
ACER Earnings
ACER Forecast & Estimates
8 analysts have analysed ACER and the average price target is 1.53 USD. This implies a price increase of 70% is expected in the next year compared to the current price of 0.9.
ACER Groups
Sector & Classification
ACER Financial Highlights
Over the last trailing twelve months ACER reported a non-GAAP Earnings per Share(EPS) of -1.66. The EPS decreased by -88.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -225.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ACER Ownership
ACER Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.18 | 921.899B | ||
| JNJ | JOHNSON & JOHNSON | 20.74 | 583.292B | ||
| MRK | MERCK & CO. INC. | 22.34 | 286.575B | ||
| PFE | PFIZER INC | 8.9 | 152.733B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.33 | 120.05B | ||
| ZTS | ZOETIS INC | 16.34 | 48.739B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.83 | 26.461B | ||
| VTRS | VIATRIS INC | 5.39 | 15.889B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.81 | 11.276B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.883B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.361B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.698B | ||
| LGND | LIGAND PHARMACEUTICALS | 23.9 | 4.217B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ACER
Company Profile
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. The company is headquartered in Newton, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2006-09-01. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Company Info
IPO: 2006-09-01
ACER THERAPEUTICS INC
One Gateway Center (300 Washington St.), Suite 356
Newton MASSACHUSETTS 02458 US
CEO: Chris Schelling
Employees: 33
Phone: 18449026100.0
ACER THERAPEUTICS INC / ACER FAQ
Can you describe the business of ACER THERAPEUTICS INC?
Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. The company is headquartered in Newton, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2006-09-01. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
What is the stock price of ACER THERAPEUTICS INC today?
The current stock price of ACER is 0.9 USD. The price increased by 3.41% in the last trading session.
Does ACER stock pay dividends?
ACER does not pay a dividend.
What is the ChartMill rating of ACER THERAPEUTICS INC stock?
ACER has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How is the valuation of ACER THERAPEUTICS INC (ACER) based on its PE ratio?
ACER THERAPEUTICS INC (ACER) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.66).
Can you provide the market cap for ACER THERAPEUTICS INC?
ACER THERAPEUTICS INC (ACER) has a market capitalization of 22.01M USD. This makes ACER a Nano Cap stock.